Unbiased AI-powered news
The account posted details from ethics filings on President Trump's 2025 trades and cryptocurrency earnings. It compared his results to those tracked on a similar Nancy Pelosi account that has operated since 2022.
Washington ExaminerAn X account titled “Donald Trump Portfolio Tracker” was suspended Thursday, one day after it launched, Washington Examiner reported. The account posted details from an Office of Government Ethics filing that showed President Trump’s $1 billion profit from trades in 2025.
A separate 937-page filing indicated that President Trump’s family cryptocurrency business earned him about $1.2 billion in 2025.
Posts from the account described a purchase of shares in a rare-earth mining company at roughly $20 per share before the Pentagon became the company’s biggest shareholder, followed by a sale after the price rose. The account’s first post stated: “He’s made billions as a politician. He’s even better than Nancy Pelosi.
Nancy Pelosi may be hotter. ” President Trump stated he does not “get involved” with the firms and advisers that manage his money. A similar account, “Nancy Pelosi Stock Tracker,” has been public since June 2022 and is run by the financial app Autopilot.
When the Trump portfolio tracker page is visited, X states the account is suspended for violating the platform’s rules. The Washington Examiner reached out to X for comment on the suspension.
Single source — no framing comparison available.
ndtv.comTesla recorded lower sales in the United States during the first half of 2026. European deliveries rose sharply after price cuts and higher fuel prices linked to the Iran war.
The Court of Justice of the European Union confirmed a 4.1 billion euro penalty against Google for bundling its search and browser apps as defaults on Android devices. The ruling ends Google's appeals process that began after the original 2018 decision.
pbs.orgThe Centers for Medicare and Medicaid Services last month proposed rules to group reformulated drugs with their originals for negotiation eligibility. The changes target biologics switched from intravenous to subcutaneous forms and would take effect with the 2029 price applicabil…